BID and lung cancer: The lung cancer H460 cells were treated with apigenin and resulted in the dose-dependent induction of morphological changes and induced DNA damage and apoptosis; the down-modulation of the protein expression of Bid, Bcl-2, and the up-regulation of protein levels of Bax decrease in the percentage of viability, caspase-3, and increased the productions of reactive oxygen species in lung cancer cells [121].